遺伝子治療の世界市場2021年-2031年

【英語タイトル】Global Gene Therapy Market 2021–2031

FactMRが出版した調査資料(FAC21NO101)・商品コード:FAC21NO101
・発行会社(調査会社):FactMR
・発行日:2021年9月
・ページ数:約170
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧、印刷不可)USD4,500 ⇒換算¥666,000見積依頼/購入/質問フォーム
Sie License(同一拠点内共有可)USD8,500 ⇒換算¥1,258,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

本調査資料では、遺伝子治療の世界市場について調査し、仮定・調査手法、エグゼクティブサマリー、市場動向、主要インサイト、製品別(イエスカルタ、キムリア、ラクスターナ、ストリムベリス、ゲンディシン)分析、用途別(眼科、腫瘍)分析、地域別分析、競争状況など、以下の構成でお届けいたします。
・仮定・調査手法
・エグゼクティブサマリー
・市場動向
・主要インサイト
・遺伝子治療の世界市場規模:製品別(イエスカルタ、キムリア、ラクスターナ、ストリムベリス、ゲンディシン)
・遺伝子治療の世界市場規模:用途別(眼科、腫瘍)
・遺伝子治療の世界市場規模:地域別
・競争状況

Gene Therapy Market- Scope of Report
A recent study by Fact.MR on the gene therapy market offers a 10-year forecast for 2021 to 2031. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering gene therapy.

The study also provides the dynamics responsible for influencing the future status of the gene therapy market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the gene therapy market, along with their product portfolios, enhances the reliability of this comprehensive research study.

Report Summary
The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of gene therapy across the globe.

A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of gene therapy products during the forecast period. Price point comparison by region with global average price is also considered in the study.

Key Questions Answered in Report
Which are the most lucrative gene therapy markets?
Which factors will impact the growth of gene therapy?
How will changing trends impact the strategies of market players?
How can market players capture the low-hanging opportunities across regions?
Which companies are leading the gene therapy industry?
What are the winning strategies of stakeholders in the market?
Analysis on Market Size Evaluation
The market has been analyzed for each segment in terms of volume (‘000 Units) and value (US$ Mn).

Estimates at global and regional levels for gene therapy are available in terms of “US$ Mn” for value and in “‘000 Units” for volume. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report.

Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global gene therapy market.

Inspected Assessment on Regional Segments
Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the gene therapy market during the forecast period.

Country-specific valuation on demand for gene therapy has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value & volume for emerging countries has also been included in the report.

In-depth Analysis on Competition Analysis
The report sheds light on leading manufacturers of gene therapy products, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in offering gene therapy has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which include essentials such as product portfolios and key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the gene therapy domain. 

Research Methodology
In Fact.MR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the gene therapy industry, and reach conclusions on the future growth parameters. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the drawn conclusions.

Secondary resources referred to by analysts during the preparation of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, all of whom have contributed to the development of the research report as a primary resource.

❖ レポートの目次 ❖

1. Preface

    1.1. Report Scope and Market Segmentation

    1.2. Research Highlights

2. Assumptions and Research Methodology

    2.1. Assumptions and Acronyms Used

    2.2. Research Methodology

3. Executive Summary

    3.1. Global Gene Therapy Market Analysis, by Region, 2021 and 2031

    3.2. Global Gene Therapy Market: Market Snapshot

4. Market Overview

    4.1. Global Gene Therapy Market Overview

    4.2. Global Gene Therapy Market Key Industry Developments

    4.3. Market Dynamics

        4.3.1. Drivers and Restraints Snapshot Analysis

        4.3.2. Drivers

        4.3.3. Restraints

        4.3.4. Opportunities

    4.4. Global Gene Therapy Market Analysis and Forecasts, 2021–2031

5. Key Insights

    5.1. Regulatory Scenario by Region/globally

    5.2. Clinical Trial Pipeline Analysis

    5.3. Overview of Manufacturers

6. Global Gene Therapy Market Analysis, by Product

    6.1. Introduction

    6.2. Key Insights

    6.3. Global Gene Therapy Market Application and Forecast, by Product

        6.3.1. Yescarta

        6.3.2. Kymriah

        6.3.3. Luxturna

        6.3.4. Strimvelis

        6.3.5. Gendicine

    6.4. Global Gene Therapy Market Analysis, by Product

    6.5. Global Gene Therapy Market Attractiveness Analysis, by Product

7. Global Gene Therapy Market Analysis, by Application

    7.1. Introduction

    7.2. Key Insights

    7.3. Global Gene Therapy Market Application and Forecast, by Application

        7.3.1. Ophthalmology

        7.3.2. Oncology

        7.3.3. Adenosine DeaminaseDeficient Severe Combined Immunodeficiency (ADA-SCID)

    7.4. Global Gene Therapy Market Analysis, by Application

    7.5. Global Gene Therapy Market Attractiveness Analysis, by Application

8. Global Gene Therapy Market Analysis, by Region

    8.1. Introduction

    8.2. Key Insights

    8.3. Global Gene Therapy Market Size and Forecast , by Region, 2016–2031

        8.3.1. United States

        8.3.2. Europe

        8.3.3. Rest of World

    8.4. Global Gene Therapy Market Analysis, by Region

    8.5. Global Gene Therapy Market Attractiveness Analysis, by Region

9. United States Gene Therapy Market Analysis

    9.1. United States Gene Therapy Market Key Findings

    9.2. United States Gene Therapy Market Overview

    9.3. United States Gene Therapy Market Size and Forecast, by Product

        9.3.1. Yescarta

        9.3.2. Kymriah

        9.3.3. Luxturna

        9.3.4. Strimvelis

        9.3.5. Gendicine

    9.4. United States Gene Therapy Market Application and Forecast, by Application

        9.4.1. Ophthalmology

        9.4.2. Oncology

        9.4.3. Adenosine DeaminaseDeficient Severe Combined Immunodeficiency (ADA-SCID)

    9.5. United States Gene Therapy Market Attractiveness Analysis

        9.5.1. By Product

        9.5.2. By Application

        9.5.3. By Country

10. Europe Gene Therapy Market Analysis

    10.1. Europe Gene Therapy Market Key Findings

    10.2. Europe Gene Therapy Market Overview

    10.3. Europe Gene Therapy Market Size and Forecast, by Product

        10.3.1. Yescarta

        10.3.2. Kymriah

        10.3.3. Luxturna

        10.3.4. Strimvelis

        10.3.5. Gendicine

    10.4. Europe Gene Therapy Market Size and Forecast, by Application

        10.4.1. Ophthalmology

        10.4.2. Oncology

        10.4.3. Adenosine DeaminaseDeficient Severe Combined Immunodeficiency (ADA-SCID)

    10.5. Europe Gene Therapy Market Forecast, by Country

        10.5.1. Germany

        10.5.2. U.K.

        10.5.3. France

        10.5.4. Spain

        10.5.5. Italy

        10.5.6. Rest of Europe

    10.6. Europe Gene Therapy Market Attractiveness Analysis

        10.6.1. By Product

        10.6.2. By Application

        10.6.3. By Country

11. Rest of World Gene Therapy Market Analysis

    11.1. Rest of World Gene Therapy Market Key Findings

    11.2. Rest of World Gene Therapy Market Overview

    11.3. Rest of World Gene Therapy Market Size and Forecast, by Product

        11.3.1. Yescarta

        11.3.2. Kymriah

        11.3.3. Luxturna

        11.3.4. Strimvelis

        11.3.5. Gendicine

    11.4. Rest of World Gene Therapy Market Size and Forecast, by Application

        11.4.1. Ophthalmology

        11.4.2. Oncology

        11.4.3. Adenosine DeaminaseDeficient Severe Combined Immunodeficiency (ADA-SCID)

    11.5. Rest of World Gene Therapy Market Attractiveness Analysis

        11.5.1. By Product

        11.5.2. By Application

        11.5.3. By Country

12. Competition Landscape

    12.1. Global Gene Therapy Market Share Analysis, by Company (2016)

    12.2. Company Profiles

        12.2.1. Novartis AG

            12.2.1.1. Overview (HQ, Employee Strength, Business Segments)

            12.2.1.2. Financials

            12.2.1.3. Recent Developments

            12.2.1.4. Strategy

        12.2.2. Orchard Therapeutics Limited.

            12.2.2.1. Overview (HQ, Employee Strength, Business Segments)

            12.2.2.2. Financials

            12.2.2.3. Recent Developments

            12.2.2.4. Strategy

        12.2.3. CELGENE CORPORATION

            12.2.3.1. Overview (HQ, Employee Strength, Business Segments)

            12.2.3.2. Financials

            12.2.3.3. Recent Developments

            12.2.3.4. Strategy

        12.2.4. Spark Therapeutics, Inc.

            12.2.4.1. Overview (HQ, Employee Strength, Business Segments)

            12.2.4.2. Financials

            12.2.4.3. Recent Developments

            12.2.4.4. Strategy

        12.2.5. Gilead Sciences, Inc.

            12.2.5.1. Overview (HQ, Employee Strength, Business Segments)

            12.2.5.2. Financials

            12.2.5.3. Recent Developments

            12.2.5.4. Strategy

        12.2.6. Sibiono GeneTech Co. Ltd.

            12.2.6.1. Overview (HQ, Employee Strength, Business Segments)

            12.2.6.2. Financials

            12.2.6.3. Recent Developments

            12.2.6.4. Strategy

Table 1: Pipeline Analysis: Gene therapy Candidates (1/8)

Table 2: Pipeline Analysis: Gene therapy Candidates (2/8)

Table 3: Pipeline Analysis: Gene therapy Candidates (3/8)

Table 4: Pipeline Analysis: Gene therapy Candidates (4/8)

Table 5: Pipeline Analysis: Gene therapy Candidates (5/8)

Table 6: Pipeline Analysis: Gene therapy Candidates (6/8)

Table 7: Pipeline Analysis: Gene therapy Candidates (7/8)

Table 8: Pipeline Analysis: Gene therapy Candidates (8/8)

Table 9: Global Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2016–2020

Table 10: Global Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2016–2020

Table 11: Global Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2021–2031

Table 12: Global Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 13: U.S. Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2016–2020

Table 14: U.S. Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2016–2020

Table 15: U.S. Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2021–2031

Table 16: U.S. Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 17: Europe Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2016–2020

Table 18: Europe Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2016–2020

Table 19: Europe Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2021–2031

Table 20: Europe Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 21: Rest of the World Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2016–2020

Table 22: Rest of the World Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2016–2020

Table 23: Rest of the World Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2021–2031

Table 24: Rest of the World Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 25: Germany Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2016–2020

Table 26: Germany Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2016–2020

Table 27: Germany Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2021–2031

Table 28: Germany Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 29: France Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2016–2020

Table 30: France Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2016–2020

Table 31: France Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2021–2031

Table 32: France Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 33: Italy Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2016–2020

Table 34: Italy Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2016–2020

Table 35: Italy Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2021–2031

Table 36: Italy Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 37: Spain Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2016–2020

Table 38: Spain Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2016–2020

Table 39: Spain Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2021–2031

Table 40: Spain Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 41: U.K. Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2016–2020

Table 42: U.K. Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2016–2020

Table 43: U.K. Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2021–2031

Table 44: U.K. Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 45: Germany Gene Therapy Market Size (US$ Mn), 2021-2031

Table 46: France Gene Therapy Market Size (US$ Mn), 2021-2031

Table 47: Italy Gene Therapy Market Size (US$ Mn), 2021-2031

Table 48: Spain Gene Therapy Market Size (US$ Mn), 2021-2031

Table 49: U.K. Gene Therapy Market Size (US$ Mn), 2021-2031

Table 50: Germany Gene Therapy Market Y-O-Y Analysis, 2021-2031

Table 51: France Gene Therapy Market Y-O-Y Analysis, 2021-2031

Table 52: Italy Gene Therapy Market Y-O-Y Analysis, 2021-2031

Table 53: Spain Gene Therapy Market Y-O-Y Analysis, 2021-2031

Table 54: U.K. Gene Therapy Market Y-O-Y Analysis, 2021-2031

Table 55: Germany Gene Therapy Market Share Analysis, 2021-2031

Table 56: France Gene Therapy Market Share Analysis, 2021-2031

Table 57: Italy Gene Therapy Market Share Analysis, 2021-2031

Table 58: Spain Gene Therapy Market Share Analysis, 2021-2031

Table 59: U.K. Gene Therapy Market Share Analysis, 2021-2031

Figure 01: Market Segmentation: Global Gene Therapy Market

Figure 02: Research Methodology: Global Gene Therapy Market

Figure 03: Analysis by Product

Figure 04: Analysis by Application

Figure 05: Analysis by Region

Figure 06: Key Industry Developments

Figure 07: Drivers and Restraints: Global Gene Therapy Market

Figure 08: Global Gene Therapy Market Value (US$ Mn) Forecast, 2021–2031

Figure 09: Global Gene Therapy Market Value Share, by Product (2016)

Figure 10: Global Gene Therapy Market Value Share, by Application (2016)

Figure 11: Global Gene Therapy Market Value Share, by Country/Region (2016)

Figure 12: Key Findings: Global Gene Therapy Market, by Product

Figure 13: Introduction: Global Gene Therapy Market, by Product

Figure 14: Global Gene Therapy Market Value Share Analysis, by Product, 2021 and 2031

Figure 15: Global Gene Therapy Market Attractiveness Analysis, by Product, 2021–2031

Figure 16: Global Gene Therapy Market Revenue (US$ Mn), by Yescarta, 2021–2031

Figure 17: Global Gene Therapy Market Revenue (US$ Mn), by Kymriah, 2021–2031

Figure 18: Global Gene Therapy Market Revenue (US$ Mn), by Luxturna, 2021–2031

Figure 19: Global Gene Therapy Market Revenue (US$ Mn), by Strimvelis, 2021–2031

Figure 20: Global Gene Therapy Market Revenue (US$ Mn), by Gendicine, 2021–2031

Figure 21: Key Findings: Global Gene Therapy Market, by Application

Figure 22: Introduction: Global Gene Therapy Market, by Application

Figure 23: Global Gene Therapy Market Value Share Analysis, by Application, 2021 and 2031

Figure 24: Global Gene Therapy Market Attractiveness Analysis, by Product, 2021–2031

Figure 25: Global Gene Therapy Market Revenue (US$ Mn ), by Ophthalmology, 2021–2031

Figure 26: Global Gene Therapy Market Revenue (US$ Mn), by Oncology, 2021–2031

Figure 27: Global Gene Therapy Market Revenue (US$ Mn ), by ADA-SCID, 2021–2031

Figure 28: U.S. Gene Therapy Market Size (U.S.$ Mn) and Y-o-Y Growth (%) Forecast, 2021–2031

Figure 29: U.S. Gene Therapy Market Value Share Analysis, by Product, 2021 and 2031

Figure 30: U.S. Gene Therapy Market Value Share Analysis, by Product, 2021 and 2031

Figure 31: U.S. Gene Therapy Market Value Share Analysis, by Application, 2021 and 2031

Figure 32: U.S. Gene Therapy Market Attractiveness Analysis, by Application, 2021–2031

Figure 33: Europe Gene Therapy Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021–2031

Figure 34: Europe Gene Therapy Market Value Share Analysis, by Product, 2021 and 2031

Figure 35: Europe Gene Therapy Market Attractiveness Analysis, by Product, 2021-2031

Figure 36: Europe Gene Therapy Market Value Share Analysis, by Application, 2021 and 2031

Figure 37: Europe Gene Therapy Market Attractiveness Analysis, by Application, 2021–2031

Figure 38: Rest of the World Gene Therapy Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021–2031

Figure 39: Rest of the World Gene Therapy Market Value Share Analysis, by Product, 2021 and 2031

Figure 40: Rest of the World Gene Therapy Market Attractiveness Analysis, by Product, 2021-2031

Figure 41: Rest of the World Gene Therapy Market Value Share Analysis, by Application, 2021 and 2031

Figure 42: Rest of the World Gene Therapy Market Attractiveness Analysis, by Application, 2021–2031

Figure 43: Competition Matrix: Global Gene Therapy Market

Figure 44: Novartis AG, Company Details

Figure 45: Novartis AG, Product Portfolio

Figure 46: Novartis AG, Breakdown of Net Sales, by Geography (2016)

Figure 47: Novartis AG, Breakdown of Net Sales, by Business Segment (2016)

Figure 48: Novartis AG, Revenue (US$ Bn) & Y-o-Y Growth (%), 2016–2016

Figure 49: Novartis AG, R&D Intensity and Sales & Marketing Intensity – Company Level, 2017–2016

Figure 50: Novartis AG, SWOT Analysis

Figure 51: Orchard Therapeutics Limited, Company Details

Figure 52: Orchard Therapeutics Limited, Product Portfolio

Figure 53: Orchard Therapeutics Limited, SWOT Analysis

Figure 54: CELGENE CORPORATION, Company Details

Figure 55: CELGENE CORPORATION, Product Portfolio

Figure 56: CELGENE CORPORATION, Revenue (US$ Bn) & Y-o-Y Growth (%), 2017–2020

Figure 57: CELGENE CORPORATION, Breakdown of Net Sales, by Key Products (2016)

Figure 58: CELGENE CORPORATION, Breakdown of Net Sales, by Geography (2016)

Figure 59: CELGENE CORPORATION, R&D Intensity and Sales & Marketing Intensity: Company Level, 2016-2017

Figure 60: CELGENE CORPORATION, SWOT Analysis

Figure 61: Spark Therapeutics, Inc., Company Details

Figure 62: Spark Therapeutics, Inc., Product Portfolio

Figure 63: Spark Therapeutics, Inc., Revenue (US$ Mn) & Y-o-Y Growth (%), 2016–2020

Figure 64: Spark Therapeutics, Inc., R&D Expenditure, 2017–2016

Figure 65: Spark Therapeutics, Inc., SWOT Analysis

Figure 66: Gilead Sciences, Inc., Company Details

Figure 67: Gilead Sciences, Inc., Product Portfolio

Figure 68: Gilead Sciences, Inc., Revenue (US$ Bn) & Y-o-Y Growth (%), 2016–2020

Figure 69: Gilead Sciences, Inc., R&D Expenditure (US$ Bn), 2016–2020

Figure 70: Gilead Sciences, Inc., SWOT Analysis

Figure 71: Sibiono GeneTech Co. Ltd, Company Details

Figure 72: Sibiono GeneTech Co. Ltd., Product Portfolio

Figure 73: Sibiono GeneTech Co. Ltd., SWOT Analysis

Figure 74: U.S. Gene Therapy Market Absolute $ Opportunity, 2021-2031

Figure 75: Germany Gene Therapy Market Absolute $ Opportunity, 2021-2031

Figure 76: France Gene Therapy Market Absolute $ Opportunity, 2021-2031

Figure 77: Italy Gene Therapy Market Absolute $ Opportunity, 2021-2031

Figure 78: Spain Gene Therapy Market Absolute $ Opportunity, 2021-2031

Figure 79: U.K. Gene Therapy Market Absolute $ Opportunity, 2021-2031

★調査レポート[遺伝子治療の世界市場2021年-2031年] (コード:FAC21NO101)販売に関する免責事項を必ずご確認ください。
★調査レポート[遺伝子治療の世界市場2021年-2031年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆